Top 4 Stocks About to Reach Their 52-Week High

A 52-week high is a technical indicator used by some of the world's top traders and investors to determine the current and future value of a stock. In this report we reveal today's top 4 stocks about to reach their 52-week highs.  ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 

Below is an important message from one of our valued partners along with today's top headlines.

Top 4 Stocks About to Reach Their 52-Week High - Ad A 52-week high is a technical indicator used by some of the world's top traders and investors to determine the current and future value of a stock. In this report we reveal today's top 4 stocks about to reach their 52-week highs. Get The Stocks Now By clicking the link above you will automatically opt-in to receive emails from ActivaTrade and agree to Privacy Policy Mark Cuban Shares Two Things He'd Do At 12 To Succeed - And They Work For Everyone Billionaire entrepreneur Mark Cuban encouraged young individuals to concentrate on reading and comprehending artificial intelligence (AI) as a means to secure their future success. Continue reading ➔ The Top AI Investment of 2025 (And It's Not AI) - Ad Because this "Miracle Metal" is not only 400 times stronger than steel... Weighs 85% less...And it conducts electricity better than copper... But it's poised to solve a $267 billion flaw threatening artificial intelligence as a whole... and could stop development in its tracks. I reveal all of the details here China learned from Trump's first trade war and changed its tactics when tariffs came again WASHINGTON (AP) — The leaders of both Canada and Mexico got on the phone with President Donald Trump this past week to on their countries, but China’s president appears unlikely to make a similar call soon. Continue reading ➔ Warren Buffett Says This Is the Most Important Financial Decision — and It's Not Investing Warren Buffett says that his success is not solely due to his financial expertise, but also hinges on his selection of a life partner. Continue reading ➔ Why Trump's Recent Moves Could Ignite a New Gold Standard - Ad Donald Trump's bold policies are driving a hidden gold market boom. Garrett Goggin, a renowned precious metals expert with 20+ years of experience, reveals 5 explosive investment opportunities set to explode in this new era. Backed by triple-digit returns in 2024, Garrett's insights show you how to position yourself for wealth in 2025. Discover Garrett's highly sought-after gold insights Bitcoin, Ethereum, Dogecoin Spike Amid High Hopes From White House Crypto Summit: This Analyst Has Some Good News For Those 'Patiently Holding' Their ETH Leading cryptocurrencies rallied on Wednesday on news that Bitcoin would be granted special status in the national strategic cryptocurrency reserve. Continue reading ➔ Tesla Out, Ford In: City Of Baltimore Goes 'In A Different Direction' Reversing EV Deal From 2024 Tesla is losing an EV city fleet deal in Baltimore to Ford. A look at what happened and how politics may have factored into the decision. Continue reading ➔ These Top 6 Utility Stocks Have Been Rising in Popularity - Ad The top utility stocks share certain characteristics that give them the power to outperform and provide steady stock returns for investors. Today we look at the markets top 6 utility companies rising in popularity. Each company on this list has the potential to provide above-average returns! Send Me a Copy Now! By clicking the link above you will automatically opt-in to receive emails from ActivaTrade and agree to Privacy Policy Intel Beats Investor Lawsuit After $32 Billion Stock Plunge—Judge Rules Foundry Losses Weren't Misleading Intel secured a legal victory after a U.S. judge dismissed a shareholder lawsuit alleging the company misled investors about foundry losses, which contributed to a $32 billion stock plunge. Continue reading ➔ North Carolina Republicans seek to force top Democrats to fall in line with Trump agenda RALEIGH, N.C. (AP) — North Carolina Republicans who are resolved to promote President Donald Trump’s agenda now seek to compel the recently elected Democratic governor to aid the president's immigration crackdown and stop the new Democratic attorney general from fighting Trump in court. Continue reading ➔ A $19 Secret to Potentially Life-Changing Gains - Ad It predicted Trump's sweeping victory. And now, this pattern says a handful of niche-sectors are poised to surge as President Trump fuels America's economic boom. For only $19, you can see how millionaire-trader Jeff Clark has used this "Magic Pattern" for over 40 years to generate over 1,000 winning trade recommendations. Go here now Canada's Liberals will elect new leader to replace Trudeau as country deals with Trump's trade war TORONTO (AP) — Canada's governing Liberals will announce a replacement for Prime Minister on Sunday as the country deals with U.S. President Donald Trump's and as a federal election looms. Continue reading ➔ One Tech Tip: Getting a lot of unwanted phone calls? Here are ways to stop them LONDON (AP) — Unwanted phone calls are out of control. Whether it's a robocall trying to sell you something or spam calls from scammers trying to rip you off, it's enough to make you want to stop answering your phone. So what can you do to stop them? Continue reading ➔ Business News Digest AP Business Digest Continue reading ➔ Fartcoin Surges 16% In A Day, Outpacing Dogecoin, Shiba Inu As Trump Crypto Summit Anticipation Builds Fartcoin (CRYPTO: FARTCOIN), one of Solana's (CRYPTO: SOL) leading meme coins, is making waves with a 16% single-day gain. Continue reading ➔ Mark Cuban Warns Elon Musk Is Making Trump's Job '1,000 Times Harder' Elon Musk, who is leading the charge at the Department of Government Efficiency, has received a warning from Mark Cuban. Continue reading ➔ South Dakota law raises questions about future of massive Midwest pipeline SIOUX FALLS, S.D. (AP) — A new law in South Dakota prohibiting the use of eminent domain to acquire land for carbon capture pipelines of a proposed 2,500 mile (4,023-kilometer) project snaking through five Midwest states. Continue reading ➔

Information, charts or examples contained in this email are for illustration and educational purposes only and not for individualized investment management. This message contains commercial elements, such as advertising as well as partner offers for which we may receive affiliate compensation. We only send these offers to those who have opted in to our newsletter. If you wish to no longer receive these offers click on the unsubscribe link at the bottom of this email. Past performance is not indicative of future results. For these reasons we strongly suggest trading in a DEMO/Simulated account. The information provided by us is for educational and informational purposes only. We make no representations or warranties concerning the products, practices or procedures of any company or entity mentioned or recommended in this email and have not determined if the statements and opinions of the advertiser are accurate, correct or truthful. If you use, act upon or make decisions in reliance on information contained in this email or any external source linked within it, you do so at your own peril and agree to hold us, our officers, directors, shareholders, affiliates and agents without fault. 339-20 De Boers Dr., Toronto, ON M3J 0H1, 917.672.7040 © 2025 Musth | PriceActionEA | All rights reserved. Unsubscribe

(Nasdaq: PALI) Makes Red To Green Move Ahead Of Lunch (Big Afternoon Ahead?)

Palisade Bio, Inc. (Nasdaq: PALI) just went red to green and maintains a hold on my watchlist's top spot.

*Sponsored StockWireNews (Nasdaq: PALI) Makes Red To Green Move Ahead Of Lunch (Big Afternoon Ahead?) March 12th Greetings Readers, Palisade Bio, Inc. (Nasdaq: PALI) just went red to green and maintains a hold on my watchlist's top spot. On top of topline data expected in the 1st half of 2025, the company dropped this significant news today: Palisade Bio Announces Two Abstracts Selected to be Showcased as Poster of Distinction and Poster Presentation at Leading GI Forum, Digestive Disease Week (DDW) 2025. Don't forget... PALI is a low float idea with roughly 1.18Mn shares in its float meaning volatility potential could be heightened. Consider getting (Nasdaq: PALI) on your screen ahead of this afternoon. ----- In the volatile world of small-cap biotechs, being prepared and informed is critical. And with my newest Nasdaq biotech breakout idea, there's four immediate points to consider: Limited (Low) Float: The profile in question has a notably low public float under 2Mn shares, which could lead to increased volatility on a daily basis. When a supply is limited like this, potential news in the future with positive sentiment could have an outsized impact in the near/short term. Recent Operational Developments: The profile has been making strategic moves in its operations, including potential expansion of manufacturing capabilities and exploring new therapeutic areas. These developments could be pivotal in determining the company's future trajectory. Sector Dynamics: The biotech industry is currently facing challenges, including rising costs and regulatory pressures. However, it's also seeing increased in-vest-ment in innovative technologies and treatments, which could benefit well-positioned companies. Analyst Targets: The most recent consensus from industry analysts indicates a significant triple-digit potential upside. These ambitious targets reflect analysts' optimism about the company's future prospects. With topline data expected in the 1st half of 2025, it may be the perfect time to take a deep-dive into this breakout idea: *Palisade Bio, Inc. (Nasdaq: PALI)* Palisade Bio is a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases. And based on several potential catalysts, PALI has topped my watchlist this week. Check them out: No. 1 - Could A Low Float Create A Volatile Situation In A Blink? No. 2 - Positive Preclinical Data Signals PALI-2108 Heading In The Right Direction. No. 3 - A Potential Upside Over 1,500% To An Analyst $14 Target? No. 4 - Palisade Announces Receipt Of CAD$1.39Mn As Reimbursement Of Prior Pre-Clinical Costs. But more on those in a second... Company Breakdown - Palisade Bio, Inc. Palisade Bio's lead program, PALI-2108, is a microbiota-activated PDE4 inhibitor prodrug in development for the treatment of moderate-to-severe ulcerative colitis. Ulcerative colitis presents a significant challenge for patients, who require therapies that provide effective remission rates, are non-immunosuppressive, and have improved safety profiles. The company employs advanced machine learning to identify patients with elevated PDE4 activity, aiming to enhance the responder population in their lead program targeting ulcerative colitis. By pinpointing key markers of colitis through RNA sequencing and meta-analysis, they identify top PDE4-effector genes, enabling them to predict potential patient responses to PDE4 inhibitors and potentially ensure targeted, effective treatment. Palisade Bio's platform technology provides the opp. to expand their pipeline across immune, inflammatory, and fibrotic diseases. This includes their program, PALI-1908, which is in preclinical development for fibrostenotic Crohn's Disease and has multiple synergies with their lead PALI-2108 program. Development Pipeline Differentiated product candidates with potential to address shortcomings of existing therapies in established markets:

Upcoming Milestones (*Estimated)

PALI-2108 - A Differentiated Approach to Ulcerative Colitis Key Differentiation: Oral Dosing Gut-restricted prodrug is bioactivated locally in the colon resulting in a longer apparent half-life and greater exposure Greater colonic tissue and lesser systemic exposure due to local bioactivation with the potential for greater efficacy and an improved safety profile Demonstrated proof-of-concept efficacy Preclinical and ex vivo data suggest potential for superior efficacy and derisks program Current Therapies for UC - Limited Efficacy with Significant Safety Concerns Though the number of available therapeutics for moderate-to-severe patients is growing, the placebo-adjusted remission rate remains low, ~10-20%, and many therapies have poor safety profiles. Absolute and Placebo-Adjusted Remission Rates at Completion of Induction (8 to 12 Weeks)

Grab Sources: PALI Website. PALI Presentation. ----- As mentioned above, (Nasdaq: PALI) has multiple potential catalysts to consider right now. Take a look: No. 1 PALI Potential Catalyst - Could A Low Float Create A Volatile Situation In A Blink? According to info from the Yahoo Finance website, PALI has a very low float. In fact, the website reports this profile to have approx. 1.18Mn shares in its float. Why is that important? It's important on one crucial level. Volatility potential. Could more positive company news in the first half of 2025 provide a near term spark? ----- No. 2 PALI Potential Catalyst - Positive Preclinical Data Signals PALI-2108 Heading In The Right Direction. Palisade Bio Presents Positive Preclinical Data of PALI-2108 for the Treatment of Ulcerative Colitis From the article: "UC patients need new oral therapies with higher remission rates, less systemic immunosuppression, and a strong safety profile. We continue to be encouraged by our preclinical and clinical results for PALI-2108, and we believe PALI-2108 could be an important option for these patients," said Mitch Jones, MD, Ph.D., Chief Medical Officer of Palisade Bio. "We are on track to report topline data in the first half of 2025 and are excited to continue exploring this novel, oral, intestinally activated PDE4 inhibitor." ----- No. 3 PALI Potential Catalyst - A Potential Upside Over 1,500% To An Analyst $14 Target? Analysts at Ladenburg Thalmann Co. Inc.—a firm with NYSE membership since 1879—published a report mentioning Palisade Bio, Inc. (Nasdaq: PALI). Ladenburg is a diversified financial services company with a history in in-vest-ment banking, equity research, institutional sales and trading, brokerage services, asset management, and trust services. Setting a $14 target for PALI, these analysts may be suggesting that this Nasdaq profile is undervalued at current levels. In fact, from PALI's opening valuation of $.8425 on Tuesday, there may be as much as 1,500+% potential upside. That's massive... ----- No. 4 PALI Potential Catalyst - Palisade Announces Receipt Of CAD$1.39Mn As Reimbursement Of Prior Pre-Clinical Costs. Palisade Bio, Inc. Announces Receipt of Cash Proceeds from Canada's SR&ED Tax Incentive Program for Reimbursement of Development Costs of PALI-2108 for Treatment of Ulcerative Colitis (UC) Company through its co-development partner, Giiant Pharma, Inc. ("Giiant"), receives funding from Canadian Scientific Research and Experimental Development (SR&ED) Tax Credit Program for PALI-2108 Ongoing progress of Palisade Bio's Phase 1a/b UC study of PALI-2108 with topline data expected in the first half of 2025 Carlsbad, CA, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) ("Palisade", "Palisade Bio", or the "Company"), a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced the receipt of CAD$1.39Mn Canadian SR&ED credits for reimbursement of prior pre-clinical costs for PALI-2108 incurred under the company's joint development plan with Giiant. "This non-dilutive funding, which resulted from our pre-clinical studies previously conducted in Montreal under our co-development agreement with Giiant, bolsters our efforts to potentially bring a solution to patients," said JD Finley, Chief Executive Officer of Palisade Bio, "We are pleased with the continued progress made with our PALI-2108 program and look forward to reporting topline data in the first half of 2025 from our ongoing Phase 1a/b study." ... Read the full article here. ----- (Nasdaq: PALI) Potential Catalysts Recap - What To Know Now No. 1 - Could A Low Float Create A Volatile Situation In A Blink? No. 2 - Positive Preclinical Data Signals PALI-2108 Heading In The Right Direction. No. 3 - A Potential Upside Over 1,500% To An Analyst $14 Target? No. 4 - Palisade Announces Receipt Of CAD$1.39Mn As Reimbursement Of Prior Pre-Clinical Costs. ----- Coverage is officially initiated on Palisade Bio, Inc. (Nasdaq: PALI). When updates are available, you'll have them quickly. Talk again shortly. Sincerely, Kai Parker StockWireNews (Always Remember The St-ock Prices Could Be Significantly Lower Now From The Dates I Provided.)

StockWireNews.com ("StockWireNews" or "SWN" ) is owned by SWN Media LLC, a single member limited liability company. Data is provided from third-party sources and SWN is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile SWN brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors. Pursuant to an agreement between SWN Media LLC and TD Media LLC, SWN Media LLC has been hired for a period beginning on 03/11/2025 and ending on 03/14/2025 to publicly disseminate information about (PALI:US) via digital communications. Under this agreement, SWN Media LLC has been paid seventeen thousand five hundred USD ("Funds"). These Funds were part of the funds that TD Media LLC received from a third party who did receive the Funds directly or indirectly from the Issuer and does not own st-ock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices. Neither SWN Media LLC, TD Media LLC and their member own shares of (PALI:US). Please see important disclosure information here: https://stockwirenews.com/disclosure/pali/#details Unsubscribe Stock Wire News 160 West Camino Real Unit 886 Boca Raton, Florida 33432 United States

News Release: Test to be sure all’s well with your water well

Test to be sure all's well with your water well More than 4 million Minnesotans rely on groundwater for their drinking water, and 1.1 million of them get that groundwater from a private well. Wells can be a source of high-quality drinking water, but they require regular maintenance. If groundwater becomes contaminated, it can affect the health of those who drink it. During National Groundwater Awareness Week — March 9-15 — officials at the Minnesota Department of Health (MDH) are reminding private well owners about the importance of yearly well testing. The five most common contaminants in Minnesota are nitrate, coliform bacteria, arsenic, lead and manganese. MDH recommends that well owners test for nitrate and coliform bacteria every year and for arsenic, lead and manganese at least once. "You can't taste, smell or see most contaminants, so testing is the only way to know how safe your water is," said MDH Water Policy Manager Tannie Eshenaur. "Well testing is particularly important if babies or pregnant people will be drinking the water." MDH recommends using an accredited laboratory for well testing (Search for Accredited Laboratories). If testing identifies any contaminants, treatment options can include: • Installing point-of-use or whole-home filters, such as reverse osmosis or a water softener. • Repairing cracks where contaminants are entering the well. • Building a new well. A limited number of grants and low-interest loans are available to help offset water treatment costs (Financial Assistance for Home Water Treatment and Well Construction, Repair, and Sealing). More information to understand well testing, results, and options for treatment is on MDH's website. -MDH- Media inquiries: Danielle Ryan MDH Communications  651-392-1097 danielle.ryan@state.mn.us You can update or cancel your subscription at any time by editing your personal profile. You will need your email address and your password (if you have selected one). P.S. If you have any questions or problems please contact subscriberhelp.govdelivery.com for assistance.  STAY CONNECTED:   MDH on X     MDH on Facebook     MDH on LinkedIn   MDH on Instagram   This email was sent to stevenmagallanes520.nims@blogger.com using GovDelivery Communications Cloud on behalf of: Minnesota Department of Health · 625 Robert Street North · St. Paul MN 55155 · 651-201-5000